Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705188 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL1170713 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL28778146 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL1111426 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2635057 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL8587069 | 0.98 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL28634065 | 0.98 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL27970025 | 0.98 | LMNA (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL28647875 | 0.87 | AKR1B1 (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL11424158 | 0.87 | AKR1B1 (0.39) | LMNAL3MBTL1TDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0824538-A1 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035700-A9 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | — | 1997-02-13 | — | — | WO | claimed |
| WO-1996035700-A1 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1996-11-14 | — | — | WO | claimed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| EP-3554505-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018107226-A1 | METHODS OF TREATING OCULAR DISORDERS | Beta Therapeutics Pty. Ltd. (AU) | 2018-06-21 | — | — | WO | disclosed |
| CN-1780643-B | Antiviral phosphonate analogs | GILEAD SCIENCES INC | 2012-04-25 | — | — | CN | disclosed |
| CN-102216325-A | Method for purifying human growth hormone polypeptides using affinity resins comprising specific ligands | NOVO NORDISK AS | 2011-10-12 | — | — | CN | disclosed |
| CN-101031306-B | Nucleoside phosphonate conjugates as anti-HIV agents | GILEAD SCIENCES INC | 2010-09-22 | — | — | CN | disclosed |
| US-7645454-B2 | Antibody or antibody fragment which binds specifically to a normal or transformed PSA glycan or glycopeptide | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-01-12 | — | — | US | disclosed |
| US-7635685-B2 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2009-12-22 | — | — | US | disclosed |
| WO-1996035700-A1 | SACCHAROPEPTIDES AND DERIVATIVES THEREOF | GLYCOMED INCORPORATED (US) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996034005-A1 | SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBR1 AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-10-31 | — | — | WO | disclosed |
| US-5543505-A | TREATMENT OF GASTROINTESTINAL DISORDERS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1995025113-A1 | SYNTHETIC COMPOUNDS WHICH BIND TO H. PYLORI, AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-09-21 | — | — | WO | disclosed |
| EP-0670677-A1 | POTENTIATOR OF $i(BACILLUS) PESTICIDAL ACTIVITY | ABBOTT LABORATORIES (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994009630-A1 | POTENTIATOR OF BACILLUS PESTICIDAL ACTIVITY | NOVO NORDISK ENTOTECH, INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0190322-B1 | PROCESS FOR THE PRODUCTION OF AMINO COMPOUNDS FROM HYDROXYL COMPOUNDS | DIAMALT AKTIENGESELLSCHAFT (DE) | 1990-10-24 | — | — | EP | disclosed |
| EP-0190322-A1 | PROCESS FOR THE PRODUCTION OF AMINO COMPOUNDS FROM HYDROXYL COMPOUNDS. | DIAMALT AG (DE) | 1986-08-13 | — | — | EP | disclosed |
| WO-1986001502-A1 | PROCESS FOR THE PRODUCTION OF AMINO COMPOUNDS FROM HYDROXYL COMPOUNDS | DIAMALT AKTIENGESELLSCHAFT (DE) | 1986-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | LMNA 2506/4885L3MBTL1 4367/4885TDP1 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.